RGNX Company Profile and Key Details

Q: Who are the executives of RGNX?

Mr. Vittal K. VasistaExecutive Vice President & Chief Financial OfficerMr. Andrew YostVice President of Corporation Devel.Mr. Kenneth T. MillsPres, Chief Executive Officer & DirectorDr. Olivier Danos Ph.D.Executive Vice President & Chief Scientific OfficerDr. Stephen Pakola M.D.Executive Vice President & Chief Medical OfficerMr. Patrick J. Christmas II, J.D.Executive Vice President & Chief Legal OfficerMs. Shiva G. FritschChief Communications Officer & Chief People OfficerDr. Ram Palanki Pharm.D.Executive Vice President of Commercial Strategy & OperationsMr. Curran M. Simpson M.S.Executive Vice President & Chief Operating OfficerDr. Laura A. Coruzzi J.D., Ph.D.Executive Vice President of Intellectual PropertyMs. Tricia TruehartHead of Investor Relations

NASDAQ : RGNX

REGENXBIO

$9.07

-0.29-3.10%

Open: 1:43 PM

69.05

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

REGENXBIO Inc. (RGNX) stock declined over -3.10%, trading at $9.07 on NASDAQ, down from the previous close of $9.36. The stock opened at $9.36, fluctuating between $9.05 and $9.42 in the recent session.

Stock Snapshot

9.36

Prev. Close

468.13M

Market Cap

9.045

Day Low

-2.41

P/E Ratio

-3.76

EPS (TTM)

-5.19

Cash Flow per Share

9.36

Open

51.61M

Number of Shares

9.42

Day High

81.98%

Free Float in %

7.08

Book Value

208.8K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 14, 2026	9.09	9.42	9.09	9.30	577.31K
Apr 13, 2026	8.79	9.15	8.71	9.04	805.87K
Apr 10, 2026	9.03	9.11	8.64	8.80	480.51K
Apr 09, 2026	8.54	9.00	8.41	8.96	470.59K
Apr 08, 2026	9.21	9.33	8.53	8.67	587.36K
Apr 07, 2026	8.76	8.94	8.49	8.80	491.94K
Apr 06, 2026	8.53	9.07	8.51	8.80	560.21K
Apr 02, 2026	8.31	8.68	8.10	8.53	417.85K
Apr 01, 2026	8.61	8.90	8.42	8.63	524.8K
Mar 31, 2026	8.05	8.53	8.04	8.38	566.68K
Mar 30, 2026	7.75	7.89	7.58	7.77	619.6K
Mar 27, 2026	8.18	8.35	7.71	7.76	625.53K
Mar 25, 2026	8.04	8.47	8.04	8.46	930.87K
Mar 24, 2026	8.13	8.23	7.74	7.81	698K
Mar 23, 2026	8.34	8.71	8.24	8.34	791.86K
Mar 20, 2026	8.33	8.48	8.07	8.10	2.68M
Mar 19, 2026	8.18	8.46	8.02	8.36	734.95K
Mar 18, 2026	8.59	8.62	8.15	8.28	640.25K
Mar 17, 2026	8.80	8.94	8.61	8.64	634.96K
Mar 16, 2026	8.70	9.00	8.66	8.79	553.91K

Contact Details

Rockville, MD 20850

United States

https://www.regenxbio.com 240 552 8181

About Company

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Stock Peers

ARGX

19.08+2.36%

argenx SE$828.35 REGN

9.05+1.21%

Regeneron Pharmaceuticals, Inc.$755.51 UTHR

0.91+0.16%

United Therapeutics Corporation$578.54 MDGL

-0.68-0.13%

Madrigal Pharmaceuticals, Inc.$524.99 VRTX

4.23+0.96%

Vertex Pharmaceuticals Incorporated$444.28 PRAX

26.6+8.39%

Praxis Precision Medicines, Inc.$343.60 ALNY

6.41+1.92%

Alnylam Pharmaceuticals, Inc.$339.41 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.59+0.97%

Krystal Biotech, Inc.$270.00 ASND

1.29+0.52%

Ascendis Pharma A/S$249.84

Company Overview

REGENXBIO Inc. (NASDAQ:RGNX) closed at $9.07 USD, losing -$0.29 (-3.10%) from the previous close of $9.36. The stock is currently mid-range between its 52-week high and low $5.85 and $16.19. With a market capitalization of about $468.13 million, REGENXBIO Inc. is classified as a small-cap and shows market-like volatility (beta ~1.13). Key stats such as the average daily volume over the past year has been around 967.99 thousand shares, volume is running light vs its 52-week average. Headquartered in Rockville, MD, REGENXBIO Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Curran Simpson, the company employs approximately 353 people and listed since September 17, 2015. REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 -5.68%, SMA50 -28.4%, SMA200 -17.22%). The stock’s 14-day RSI is 37.87 (weak momentum), while the ATR of 0.81 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.95% below its high and over 73.78% above its low. Average 10-day trading volume of 567.68 thousand shares is below the 3-month average of 948.15 thousand, indicating normal recent market interest.

Valuation Metrics

REGENXBIO Inc. trades at a P/E ratio of -2.48, slightly below the S&P 500 average, with a price-to-sales ratio of 2.82 and a price-to-book ratio of 4.69 trading at moderately above to book value. The P/FCF stands at -3.8, also above market averages.

Dividend & Fair Value

REGENXBIO Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.27. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

REGENXBIO Inc. generated EPS of -$3.49 over the past year. Five-year average earnings growth is -12.18%. Wall Street analysts project EPS growth of 20.2% annually over the next five years. The latest quarter delivered EPS of -$1.20. The next quarter is forecast at -$0.96. Next year's EPS is expected at $48.52. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 11 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $52.00 to $14.00. The high target offers 459.14% upside. The low target suggests 50.54% downside. The mean target is $34.61. This offers 272.15% upside. REGENXBIO Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -13.16%. The prior quarter beat by 22.12%. Over the last six quarters, Apple has recorded several small beats. These include -18.6% in August 01, 2024.

Shareholding & Insider Activity

REGENXBIO Inc. has 50.51 million shares outstanding. The public float is 41.42 million shares, elevated short interest at 13.15% of float. This equals 5.47 million shares. The short ratio is 8.16 days. Institutional investors hold 94.69% of the float. Insiders own 7.65%. Fox Allan M. holds 1.53 million shares, Mills Kenneth T. has 475.10 thousand shares and PAKOLA STEVE has 247.93 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.12 thousand shares across 1 transactions.

Financial & Profitability Overview

Over the trailing twelve months, REGENXBIO generated $90.24M in revenue, or $2.06 per share. Gross margin was 39.57%, operating margin -297.12%, and net profit margin -291.99%. Returns are negative, with ROA at -45.91% and ROE at -84.52%.
On valuation metrics, REGENXBIO trades at a P/E of -2.48, P/S of 2.82 and P/B of 4.69. The current ratio is 2.38 and quick ratio is 2.38. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -40.59 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 2.54, supported by a cash flow-to-debt ratio of -0.48.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, REGENXBIO posted revenue of $90.24M, down slightly from $112.72M in the prior quarter. Gross profit was $35.71M (margin 39.57%). Operating income was - $268.13M (margin -297.1%). Net income was- $263.49M (EPS - $6.02).
The company ended the quarter with $275.26M in cash and short-term investments, a total debt of $89.29M, and net debt of $54.77M. Total assets were $573.97M, with equity of $311.74M. Financials further reflected weakness, with operating cash flow of - $218.41M, free cash flow of - $228.37M, and capital expenditures of - $9.96M.

Price Forecast & Outlook

Our AI price prediction model suggests that REGENXBIO Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.37%, with price expected at $9.08 by April 28, 2026, within a range of $8.45 to $9.76 3-Month Outlook: Projected rise of 18.71%, reaching $11.04 by July 13, 2026, with a range of $10.53 to $11.58. 1-Year Outlook: Projected gain of 70.11%, with price at $15.82 by April 14, 2027, within a range of $1.44 to $22.06.

Key Takeaways

REGENXBIO Inc. (NASDAQ:RGNX) shares are flat -2.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows REGENXBIO Inc. trading at a premium to the broader market with a P/E of -2.48. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $46.32, suggesting 398.06% upside. Our AI forecast model points to short-term weakness (-2.37% over two weeks), a medium-term rise (18.71% over three months), and a longer-term gain (70.11% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current REGENXBIO Inc. (RGNX) stock price?

REGENXBIO Inc. (NASDAQ: RGNX) stock price is $9.07 in the last trading session. During the trading session, RGNX stock reached the peak price of $9.42 while $9.05 was the lowest point it dropped to. The percentage change in RGNX stock occurred in the recent session was -3.1% while the dollar amount for the price change in RGNX stock was - $0.29.

RGNX's industry and sector of operation?

The NASDAQ listed RGNX is part of Biotechnology industry that operates in the broader Healthcare sector. REGENXBIO Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of RGNX?

Mr. Vittal K. Vasista
Executive Vice President & Chief Financial Officer
Mr. Andrew Yost
Vice President of Corporation Devel.
Mr. Kenneth T. Mills
Pres, Chief Executive Officer & Director
Dr. Olivier Danos Ph.D.
Executive Vice President & Chief Scientific Officer
Dr. Stephen Pakola M.D.
Executive Vice President & Chief Medical Officer
Mr. Patrick J. Christmas II, J.D.
Executive Vice President & Chief Legal Officer
Ms. Shiva G. Fritsch
Chief Communications Officer & Chief People Officer
Dr. Ram Palanki Pharm.D.
Executive Vice President of Commercial Strategy & Operations
Mr. Curran M. Simpson M.S.
Executive Vice President & Chief Operating Officer
Dr. Laura A. Coruzzi J.D., Ph.D.
Executive Vice President of Intellectual Property
Ms. Tricia Truehart
Head of Investor Relations

How RGNX did perform over past 52-week?

RGNX's closing price is 58.97% higher than its 52-week low of $5.85 where as its distance from 52-week high of $16.19 is -42.56%.

How many employees does RGNX have?

Number of RGNX employees currently stands at 353.

Link for RGNX official website?

Official Website of RGNX is: https://www.regenxbio.com

How do I contact RGNX?

RGNX could be contacted at phone 240 552 8181 and can also be accessed through its website. RGNX operates from 9804 Medical Center Drive, Rockville, MD 20850, United States.

How many shares of RGNX are traded daily?

RGNX stock volume for the day was 208.8K shares. The average number of RGNX shares traded daily for last 3 months was 967.99K.

What is the market cap of RGNX currently?

The market value of RGNX currently stands at $468.13M with its latest stock price at $9.07 and 51.61M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	353
Beta	1.14
Sales or Revenue	$90.24M
5Y Sales Change%	-0.654%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

RGNX Company Profile and Key Details

REGENXBIO

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Price Forecast & Outlook

Valuation Metrics